论文部分内容阅读
以往含磺胺药和磺胺增效剂的注射剂存在一些缺点。如制品pH值往往较高,注射时注射部位的组织受损害,静注时有时发生溶血或在血管内形成血块;而且这类注射剂加到微酸性或中性静注液或滴注液(如盐水和葡萄糖)中时,可产生不溶性的磺胺药及磺胺增效剂络合物;此外,这类高碱性注射剂经121℃、20分钟热压灭菌时,制品中的磺胺药易被氧化而色变黄。因此,需要一种新的和改进的注射液,以克服原方法生产注射剂的缺点。本专利能克服上述缺点,如当直接缓慢注射到静脉内,不产生血块或组织损害;与酸性或中性静脉
In the past with sulfa drugs and sulfonamide synergistic injection there are some shortcomings. Such as the pH value of the product is often higher, the injection site tissue damage at the injection, intravenous sometimes hemolysis or blood clots in the blood vessels; and such injection into the slightly acidic or neutral intravenous fluids or instillation solution (such as Saline and glucose), can produce insoluble sulfa drugs and sulfonamide synergist complexes; In addition, such over-the-counter injection at 121 ℃, 20 minutes autoclaving, the products sulfonamides easily oxidized The color turns yellow. Therefore, there is a need for a new and improved injection solution to overcome the disadvantages of the original method of producing an injection. The patent can overcome the above shortcomings, such as when injected directly into the vein without causing blood clots or tissue damage; and acidic or neutral vein